Calidi Biotherapeutics (NYSEMKT: CLDI) reported Q2 2023 earnings per share (EPS) of -$0.46, up 428.57% year over year. Total Calidi Biotherapeutics earnings for the quarter were -$4.27 million. In the same quarter last year, Calidi Biotherapeutics's earnings per share (EPS) was $0.14.
As of Q4 2023, Calidi Biotherapeutics's earnings has grown year over year. Calidi Biotherapeutics's earnings in the past year totalled -$8.59 million.
What was CLDI's revenue last quarter?
Calidi Biotherapeutics (NYSEMKT: CLDI) reported Q2 2023 revenue of $0.00 up N/A year over year. In the same quarter last year, Calidi Biotherapeutics's revenue was $0.00.
What was CLDI's revenue growth in the past year?
As of Q4 2023, Calidi Biotherapeutics's revenue has grown -100% year over year. This is 199.5 percentage points lower than the US Biotechnology industry revenue growth rate of 99.5%. Calidi Biotherapeutics's revenue in the past year totalled $0.00.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.